BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 15610828)

  • 1. Treatment for substance use disorders in a privately insured population under managed care: costs and services use.
    Greenfield SF; Azzone V; Huskamp H; Cuffel B; Croghan T; Goldman W; Frank RG
    J Subst Abuse Treat; 2004 Dec; 27(4):265-75. PubMed ID: 15610828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managed care and the quality of substance abuse treatment.
    Shepard DS; Daley M; Ritter GA; Hodgkin D; Beinecke RH
    J Ment Health Policy Econ; 2002 Dec; 5(4):163-74. PubMed ID: 14578550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of mental health utilization and costs among children in a privately insured population.
    Leslie DL; Rosenheck RA; Horwitz SM
    Health Serv Res; 2001 Apr; 36(1 Pt 1):113-27. PubMed ID: 11324739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managed care, networks and trends in hospital care for mental health and substance abuse treatment in Massachusetts: 1994-1999.
    Fleming E; Lien H; Ma CT; McGuire TG
    J Ment Health Policy Econ; 2003 Mar; 6(1):3-12. PubMed ID: 14578543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral health insurance parity for federal employees.
    Goldman HH; Frank RG; Burnam MA; Huskamp HA; Ridgely MS; Normand SL; Young AS; Barry CL; Azzone V; Busch AB; Azrin ST; Moran G; Lichtenstein C; Blasinsky M
    N Engl J Med; 2006 Mar; 354(13):1378-86. PubMed ID: 16571881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mental health care utilization and costs in a corporate setting.
    Tsai SP; Bernacki EJ; Reedy SM
    J Occup Med; 1987 Oct; 29(10):812-6. PubMed ID: 3681492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The decline in receipt of substance abuse treatment by the privately insured, 1992-2001.
    Mark TL; Coffey RM
    Health Aff (Millwood); 2004; 23(6):157-62. PubMed ID: 15537594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. U.S. spending for mental health and substance abuse treatment, 1991-2001.
    Mark TL; Coffey RM; Vandivort-Warren R; Harwood HJ; King EC;
    Health Aff (Millwood); 2005; Suppl Web Exclusives():W5-133-W5-142. PubMed ID: 15797947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What should non-US behavioral health systems learn from the USA?: US behavior health services trends in the 1980s and 1990s.
    Kishi Y; Kathol RG; McAlpine DD; Meller WH; Richards SW
    Psychiatry Clin Neurosci; 2006 Jun; 60(3):261-70. PubMed ID: 16732740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs of physical and mental comorbidities among employees: a comparison of those with and without bipolar disorder.
    Rajagopalan K; Kleinman NL; Brook RA; Gardner HH; Brizee TJ; Smeeding JE
    Curr Med Res Opin; 2006 Mar; 22(3):443-52. PubMed ID: 16574028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The quiet epidemic.
    Ryan P
    Calif Hosp; 1993; 7(1):8-11. PubMed ID: 10171358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of managed behavorial healthcare on the costs of psychiatric and chemical dependency treatment.
    Geraty R; Bartlett J; Hill E; Lee F; Shusterman A; Waxman A
    Behav Healthc Tomorrow; 1994; 3(2):18-30. PubMed ID: 10172255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
    Feldman SR; Evans C; Russell MW
    J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychiatric inpatient, outpatient, and medication utilization and costs among privately insured youths, 1997-2000.
    Martin A; Leslie D
    Am J Psychiatry; 2003 Apr; 160(4):757-64. PubMed ID: 12668366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Episodes of mental health and substance abuse treatment under a managed behavioral health care carve-out.
    Huskamp HA
    Inquiry; 1999; 36(2):147-61. PubMed ID: 10459370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unmet substance abuse treatment need, health services utilization, and cost: a population-based emergency department study.
    Rockett IR; Putnam SL; Jia H; Chang CF; Smith GS
    Ann Emerg Med; 2005 Feb; 45(2):118-27. PubMed ID: 15671966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The costs of behavioral health care coverage.
    Sterman P
    Empl Benefits J; 1997 Mar; 22(1):2-10. PubMed ID: 10172938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic costs of benign prostatic hyperplasia in the private sector.
    Saigal CS; Joyce G
    J Urol; 2005 Apr; 173(4):1309-13. PubMed ID: 15758787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.